摘要
目的:探讨依达拉奉联合丹红注射液治疗急性脑梗死(acute cerebral infarct,ACI)患者的有效性和安全性。方法:选取2019年6月—2021年5月南阳市第一人民医院收治的75例急性脑梗死患者,根据单盲分组法分为常规治疗组38例,予常规治疗联合应用依达拉奉注射液;联合治疗组37例,予常规治疗联合应用依达拉奉及丹红注射液。比较两组患者的临床应用效果,包括治疗有效率、神经功能评价、生存质量评价和不良反应发生率。结果:治疗后,两组患者神经功能评价、生存质量评价评分均较治疗前改善,对比常规治疗组,联合治疗组评分更具优势,差异有统计学意义(t=42.154、7.791、11.747,P<0.05);两组患者治疗有效率对比,联合治疗组(89.19%)高于常规治疗组(68.42%),差异有统计学意义(χ2=4.818,P<0.05);两组患者不良反应发生率相比,差异无统计学意义(P>0.05)。结论:依达拉奉联合丹红注射液治疗ACI患者未增加其不良反应发生情况,对改善患者预后有利,治疗具有有效性及安全性。
Objective:To investigate the efficacy and safety of edaravone combined with Danhong injection in the treatment of acute cerebral infarction.Methods:A total of 75 patients with acute cerebral infarction admitted to the hospital from June 2019 to May 2021 were selected.According to single blind grouping method,38 patients were divided into conventional treatment group and received conventional treatment combined with edaravone injection.The other patients were included in the combined treat⁃ment group and received conventional treatment combined with edaravone and danhong injection.The clinical application efficacy of the two groups was compared,including the treatment effective rate,neurological function evaluation,quality of life evaluation and the incidence of adverse reactions.Results:After treatment,the neurological function evaluation and survival quality evalua⁃tion scores improved in both groups compared with those before treatment,and the scores in the combined treatment group were higher than those in the conventional treatment group,with statistically significant differences(t=42.154,7.791,11.747,P<0.05).The treatment efficiency of the combined treatment group was 89.19%,higher than 68.42%in the conventional treatment group,and the difference was statistically significant(χ2=4.818,P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The treatment of patients with ACI with edaravone combined with Danhong injection did not increase the incidence of adverse reactions and was beneficial in improving the prognosis of pa⁃tients,and the treatment was effective and safe.
作者
杨道迪
方敬献
YANG Dao-di;FANG Jing-xian(Nanyang First People’s Hospital,Nanyang,Henan,473000,China)
出处
《黑龙江医学》
2023年第6期692-694,共3页
Heilongjiang Medical Journal
关键词
丹红注射液
依达拉奉
急性脑梗死
安全性
有效性
Danhong injection
Edaravone
Acute cerebral infarction
Security
Effectiveness
